Table 3.
Demographic and clinico-pathological characteristics of patients with EGFR mutant aNSCLC progressing on EGFR TKIs and developing an FGFR3-TACC3 fusion. All FGFR3-TACC3 fusions were detected by Guardant 360.
| Case Number | Sex | Age, Years | Tumor Histology | Smoking History | EGFR Mutation Subtype | Treatment History before FGFR3-TACC3 Fusion Diagnosis: Agent (PFS, mo) | FGFR3-TACC3 Fusion MAF, % | Concurrent Alterations, MAF, % |
|---|---|---|---|---|---|---|---|---|
| #1 | F | 59 | ADC | Never- smoker |
L858R | Gefitinib (7 mo), osimertinib (13 mo), carboplatin/pemetrexed (6 mo) | 0.3 |
EGFR L858R, 33.4, PIK3CA E545K, 47.5, CCND1 amplification, CDK4 amplification, KRAS amplification, MYC amplification |
| #2 | M | 84 | ADC | Never- smoker |
E746_A750del | Osimertinib (11 mo) | 0.04 |
EGFR E746_A750del, 1.3, TP53 Y163C, 0.4 |
| #3 | F | 63 | ADC | Never- smoker |
L747_A750delinsP | Gefitinib (52 mo), osimertinib (14 mo) | 0.07 | Gardant360: EGFR L747_A750delinsP, 0.5, PIK3CA V344G, 1.3 Tempus xT: EGFR L747_A750delinsP, 14.4, EGFR p. C797S, 3.6, PIK3CA V344G, 15.9 |
Abbreviations: ADC—adenocarcinoma; EGFR—epidermal growth factor receptor; F—female; FGFR—fibroblast growth factor receptor; M—male; MAF—mutant allele frequency; mo—months; PFS—progression-free survival.